576 related articles for article (PubMed ID: 12814173)
21. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
22. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
23. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
24. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.
Hohol MJ; Orav EJ; Weiner HL
Mult Scler; 1999 Oct; 5(5):349-54. PubMed ID: 10516779
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
Thouvenot E; Orsini M; Daures JP; Camu W
Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
[TBL] [Abstract][Full Text] [Related]
26. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.
Kremenchutzky M; Cottrell D; Rice G; Hader W; Baskerville J; Koopman W; Ebers GC
Brain; 1999 Oct; 122 ( Pt 10)():1941-50. PubMed ID: 10506095
[TBL] [Abstract][Full Text] [Related]
27. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
Trojano M; Paolicelli D; Bellacosa A; Cataldo S
Neurol Sci; 2003 Dec; 24 Suppl 5():S268-70. PubMed ID: 14652786
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.
Vukusic S; Confavreux C
J Neurol Sci; 2003 Feb; 206(2):135-7. PubMed ID: 12559500
[TBL] [Abstract][Full Text] [Related]
29. Progression in familial and nonfamilial MS.
Koch M; Uyttenboogaart M; Heerings M; Heersema D; Mostert J; De Keyser J
Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881
[TBL] [Abstract][Full Text] [Related]
30. Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
Scalfari A; Neuhaus A; Daumer M; Muraro PA; Ebers GC
J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):67-75. PubMed ID: 23486991
[TBL] [Abstract][Full Text] [Related]
31. Disability progression in multiple sclerosis: a Tunisian prospective cohort study.
Hentati E; Ben Sassi S; Nabli F; Mabrouk T; Zouari M; Hentati F
Neurol Sci; 2018 May; 39(5):879-884. PubMed ID: 29476286
[TBL] [Abstract][Full Text] [Related]
32. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
33. Long-term evolution of multiple sclerosis disability in the treatment era.
; Cree BA; Gourraud PA; Oksenberg JR; Bevan C; Crabtree-Hartman E; Gelfand JM; Goodin DS; Graves J; Green AJ; Mowry E; Okuda DT; Pelletier D; von Büdingen HC; Zamvil SS; Agrawal A; Caillier S; Ciocca C; Gomez R; Kanner R; Lincoln R; Lizee A; Qualley P; Santaniello A; Suleiman L; Bucci M; Panara V; Papinutto N; Stern WA; Zhu AH; Cutter GR; Baranzini S; Henry RG; Hauser SL
Ann Neurol; 2016 Oct; 80(4):499-510. PubMed ID: 27464262
[TBL] [Abstract][Full Text] [Related]
34. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course.
Galimberti D; Scalabrini D; Fenoglio C; Comi C; De Riz M; Venturelli E; Lovati C; Mariani C; Monaco F; Bresolin N; Scarpini E
Eur J Neurol; 2007 Feb; 14(2):162-7. PubMed ID: 17250724
[TBL] [Abstract][Full Text] [Related]
35. Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort.
Alroughani RA; Akhtar S; Ahmed SF; Al-Hashel JY
Int J Neurosci; 2015; 125(11):831-7. PubMed ID: 25329929
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
37. High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study.
Casanova B; Coret F; Valero C; Landete L; Pascual A; Vilchez JJ
Mult Scler; 2002 Feb; 8(1):59-63. PubMed ID: 11939173
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process.
Zhang Y; Taylor BV; Simpson S; Blizzard L; van der Mei I
Eur J Neurol; 2019 Jan; 26(1):155-161. PubMed ID: 30133059
[TBL] [Abstract][Full Text] [Related]
39. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension.
Myhr KM; Riise T; Vedeler C; Nortvedt MW; Grønning R; Midgard R; Nyland HI
Mult Scler; 2001 Feb; 7(1):59-65. PubMed ID: 11321195
[TBL] [Abstract][Full Text] [Related]
40. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.
Kantarci OH; Lebrun C; Siva A; Keegan MB; Azevedo CJ; Inglese M; Tintoré M; Newton BD; Durand-Dubief F; Amato MP; De Stefano N; Sormani MP; Pelletier D; Okuda DT
Ann Neurol; 2016 Feb; 79(2):288-94. PubMed ID: 26599831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
